<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00329927</url>
  </required_header>
  <id_info>
    <org_study_id>V70P4S</org_study_id>
    <secondary_id>Eudract number</secondary_id>
    <secondary_id>2006-000610-20</secondary_id>
    <nct_id>NCT00329927</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly Subjects</brief_title>
  <official_title>A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, (Adjuvanted With MF59C.1) Influenza Vaccine, Formulation 2006-2007, When Administered to Elderly Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To evaluate the antibody response to each influenza vaccine antigen when administering a
      single dose to subjects aged 65 years and over
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CHMP criteria for evaluation of flu vaccines e.g Seroprotection, GMR's and Seroconversion rate at day 21 following vaccination.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one local reaction between Day 0 and Day 3 after vaccine injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one systemic reaction between Day 0 and Day 3 after vaccine injection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of subjects with at least one adverse event between Day 0 and the study termination visit (Day 21, window: 20-24).</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  65 years of age or older

        Exclusion Criteria:

          -  any serious disease such as cancer, autoimmune disease, advanced arteriosclerotic
             disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD)
             that requires oxygen therapy, acute or progressive hepatic disease, acute or
             progressive renal disease, congestive heart failure and bleeding diathesis or
             conditions associated with prolonged bleeding time

          -  hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,
             neomycin or polymyxin or any other component of the vaccine - - history of
             neurological symptoms or signs, or anaphylactic shock following administration of any
             vaccine

          -  known or suspected (or high risk of developing) impairment/alteration of immune
             function within the past 7 days

          -  any acute disease or infections requiring systemic antibiotic or antiviral therapy
             fever within the past 3 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines - Drug Information Services</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Medicina e Scienze dell’Invecchiamento, Università G. D'Annunzio</name>
      <address>
        <city>Via dei Vestini</city>
        <state>Chieti</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ufficio Igiene e Sanità Pubblica di Lanciano, Via S. Spaventa, 37</name>
      <address>
        <city>Lanciano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2006</study_first_submitted>
  <study_first_submitted_qc>May 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2006</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>Adjuvanted Influenza Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

